Epizyme appoints Dr. Roy Beveridge and Carol Stuckley to its Board of Directors

– USA, MA –  Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced the appointments of Dr. Roy Beveridge (M.D.) and Carol Stuckley to its Board of Directors, effective November 16, 2021.

The Company also announced that Dr. Andrew Allen has resigned from this position, effective November 16, 2021.

“As Epizyme launches into its next phase of growth, the addition of Roy and Carol and their distinguished and complementary skillsets will help us further strengthen and diversify our Board,” said Board Chairman, David Mott. “I look forward to working alongside them as Epizyme seeks to fulfill its vision of developing transformative epigenetic medicines for people living with cancer. I would also like to thank Andrew for his dedication and commitment to Epizyme over the last seven years. His input and guidance to the Company have been invaluable, and we wish him well.”

“We are delighted to welcome Roy and Carol to our Board of Directors as we broaden our portfolio and solidify our leadership in epigenetic therapies,” said CEO, Grant Bogle. “Roy’s broad experience as a practicing clinical oncologist and researcher, coupled with his executive leadership roles as CMO for both Humana Inc. and US Oncology, Inc., brings crucial payer and provider insights to Epizyme as we deepen our focus on supporting physicians in delivering optimal care to the patients and communities they serve. Carol’s 25+ years of executive leadership in the healthcare industry, including more than 22 years at Pfizer, coupled with her multinational finance and accounting expertise, make her an ideal director to serve on the Epizyme Board as our commercial activities accelerate. We also want to recognize and thank Andrew for his many contributions over his years of service, helping us transition Epizyme to a fully integrated biopharmaceutical company during his seven years on our Board.”

About Dr. Roy A. Beveridge

Dr. Roy Beveridge is a medical oncologist who has been in practice for more than 30 years during which time he has treated hundreds of lymphoma and myeloma patients. He has led large integrated provider networks and has deep expertise in healthcare policy and reimbursement. Previously, Dr. Beveridge served as Humana Inc.’s CMO, where he led clinical policy, population health, and clinical quality initiatives. Before this Dr. Beveridge held a similar role for US Oncology, which was acquired by McKesson Specialty Health, where he focused on research, quality, data science, clinical pathways, and payer initiatives. Much of his recent work has focused on social determinants of health and improving the health of underserved populations. He has published more than 200 papers in various professional and scientific journals. Dr. Beveridge is currently a Strategy and Policy Consultant at Avalere Health, a healthcare consulting firm, and his additional professional experiences include working as a Consultant to Humana and serving as Interim President of Conviva Physician Group, a wholly-owned subsidiary of Humana.

Dr. Beveridge holds a B.A. in Biology from Johns Hopkins University and an M.D. from Cornell University. He also received internal medicine training at the University of Chicago and completed an oncology fellowship at Johns Hopkins University.

About Carol Stuckley

Carol Stuckley, M.B.A., is a finance executive with significant experience leading the financial aspects of large global healthcare companies. Ms. Stuckley spent more than 22 years at Pfizer, Inc. in a variety of global financial roles of increasing responsibility, most recently as VP, Assistant Treasurer, and Corporate Officer. She currently serves on the Board of Directors of Centessa Pharmaceuticals plc, a publicly-traded clinical-stage pharmaceutical company, and previously served on the Board of Directors of Ipsen S.A., a publicly traded, French pharmaceutical company. Ms. Stuckley recently served as the CFO and SVP at Healthcare Payment Specialists, LLC, and as VP, Finance North America at Galderma Laboratories, L.P.

Ms. Stuckley earned a B.A. in Economics and French from the University of Delaware, as well as an M.B.A. in International Business and Finance and an M.A. in Economics from the Fox Business School at Temple University.

About Epizyme, Inc.

Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer through novel epigenetic medicines. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take, and based on a deep understanding of the patients that may benefit from them. The Company aspires to change the standard of care for patients and physicians by developing medicines with fundamentally new mechanisms of action.

For more information: https://www.epizyme.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.